Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ADPT 
Adaptive Biotechnologies Corp (ADPT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/10/2025: ADPT (4-star) is a SELL. SELL since 1 days. Simulated Profits (21.07%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $17.86
1 Year Target Price $17.86
| 3 | Strong Buy |
| 4 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -36.04% | Avg. Invested days 34 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/10/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.26B USD | Price to earnings Ratio - | 1Y Target Price 17.86 |
Price to earnings Ratio - | 1Y Target Price 17.86 | ||
Volume (30-day avg) 8 | Beta 2.22 | 52 Weeks Range 4.27 - 17.89 | Updated Date 11/10/2025 |
52 Weeks Range 4.27 - 17.89 | Updated Date 11/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.52 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-06 | When After Market | Estimate -0.18 | Actual 0.06 |
Profitability
Profit Margin -31.5% | Operating Margin (TTM) 10.95% |
Management Effectiveness
Return on Assets (TTM) -9.32% | Return on Equity (TTM) -37.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2054877549 | Price to Sales(TTM) 8.93 |
Enterprise Value 2054877549 | Price to Sales(TTM) 8.93 | ||
Enterprise Value to Revenue 10.01 | Enterprise Value to EBITDA -1 | Shares Outstanding 152665188 | Shares Floating 117759819 |
Shares Outstanding 152665188 | Shares Floating 117759819 | ||
Percent Insiders 2.34 | Percent Institutions 98.17 |
Upturn AI SWOT
Adaptive Biotechnologies Corp
Company Overview
History and Background
Adaptive Biotechnologies Corp. was founded in 2009. It leverages sequencing to map T-cell and B-cell receptors of the immune system. Initially focused on research, it has expanded into clinical diagnostics and drug discovery partnerships.
Core Business Areas
- Minimal Residual Disease (MRD): ClonoSEQ is Adaptive's core MRD test, used to detect and monitor minimal residual disease in patients with certain blood cancers. It's used by physicians to inform treatment decisions.
- Drug Discovery: Adaptive partners with pharmaceutical companies to identify and develop novel therapeutics by leveraging its immune medicine platform. This involves identifying targets and developing antibodies based on immune responses.
Leadership and Structure
Adaptive Biotechnologies is led by CEO Rama Alapati. The company has a board of directors that oversees its strategy and operations. The structure is functional, with departments for research, development, commercialization, and operations.
Top Products and Market Share
Key Offerings
- ClonoSEQ: ClonoSEQ is a test that detects minimal residual disease in blood cancers. Market share data is difficult to pinpoint precisely, but it's a leading test in the MRD space. Competitors include Invitae (NVTA) and Labcorp (LH).
- Drug Discovery Partnerships: Adaptive partners with pharmaceutical companies such as Genentech and Amgen to discover and develop new drugs using its immune medicine platform. Revenue fluctuates depending on milestones reached in these partnerships. Competitors depend on specific targets, but overall the drug discovery market is crowded.
Market Dynamics
Industry Overview
The industry involves immune-driven diagnostics and therapeutics, encompassing fields like oncology, autoimmune diseases, and infectious diseases. The industry is experiencing rapid growth due to advances in sequencing and immunology.
Positioning
Adaptive is a leader in mapping the adaptive immune system, with a strong position in MRD testing and growing presence in drug discovery. Its competitive advantage lies in its proprietary sequencing platform and large immune repertoire database.
Total Addressable Market (TAM)
The total addressable market for immune-driven diagnostics and therapeutics is estimated to be in the tens of billions of dollars. Adaptive is positioned to capture a significant portion of this TAM with its MRD testing and drug discovery partnerships. Exact TAM is highly variable depending on definitions.
Upturn SWOT Analysis
Strengths
- Proprietary sequencing platform
- Large immune repertoire database
- Established partnerships with pharmaceutical companies
- Leading position in MRD testing
Weaknesses
- Limited profitability
- Reliance on partnerships for drug discovery revenue
- Competition in MRD testing
- Cash burn rate
Opportunities
- Expanding MRD testing to new indications
- Securing new drug discovery partnerships
- Developing new diagnostics and therapeutics
- Expanding into new geographic markets
Threats
- Competition from other diagnostic and therapeutic companies
- Changes in reimbursement policies
- Failure to secure new partnerships
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- Invitae (NVTA)
- Guardant Health (GH)
- NeoGenomics (NEO)
Competitive Landscape
Adaptive has a strong competitive position in MRD testing with ClonoSEQ, but faces increasing competition from Invitae and others. Its drug discovery partnerships provide a unique advantage, but success depends on the progress of partnered programs. Guardant Health is a broader oncology diagnostics company that has a different positioning.
Growth Trajectory and Initiatives
Historical Growth: Historical revenue growth would be documented through growth rates across the past years based on reported filings.
Future Projections: Analyst revenue projections and growth estimates would be sourced from financial analysis platforms such as Yahoo Finance, MarketWatch and others.
Recent Initiatives: Recent initiatives are focused on expanding ClonoSEQ's applications and forging partnerships for novel drug discovery efforts.
Summary
Adaptive Biotechnologies is a leading immune medicine company with a strong position in MRD testing through ClonoSEQ. Its drug discovery partnerships are promising, but success depends on the progress of these programs. The company faces competition in diagnostics and needs to manage its cash burn to achieve profitability. Expansion of ClonoSEQ and securing new partnerships are crucial for future growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Adaptive Biotechnologies Corp. Investor Relations
- SEC Filings
- Industry Reports
- Financial News Outlets
- Analyst Reports
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Market share estimates are approximate and based on available data.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Adaptive Biotechnologies Corp
Exchange NASDAQ | Headquaters Seattle, WA, United States | ||
IPO Launch date 2019-06-27 | Co-Founder, CEO & Chairman Mr. Chad M. Robins M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 619 | Website https://www.adaptivebiotech.com |
Full time employees 619 | Website https://www.adaptivebiotech.com | ||
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. It has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.